External broker reports(aggregated public sources), ICICI Securities Ltd

ICICI Securities Limited

ICICI Securities Limited provides investment services. The Company provides corporate and investment banking, securities, wealth management, retail brokerage, initial public offerings, and advisory services. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

ICICI Securities Ltd

ICICI Securities Limited provides investment services. The Company provides corporate and investment banking, securities, wealth management, retail brokerage, initial public offerings, and advisory services. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Metropolis Healthcare Limited / Equity Bottom-Up

Metropolis Healthcare Limited (METROHL IN)

<ul><li>Metropolis’ Q3FY25 result was impacted by lower sales from institutional biz (2% impact on revenue) and muted growth in acute ailment tests.</li><li>In last 4 years, Metropolis has widened its lab network by 68% to 209 labs in 9MFY25. With sufficient lab network in place, the company’s focus ahead is on adding spokes and the target is to have 30 collection centres per lab as against 21 currently.</li><li>Besides, new lab additions have dented its EBITDA margin by 100-150bps and the impact is likely to reverse ahead on the back of price hikes and operating leverage.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Metropolis’ Q3FY25 result was impacted by lower sales from institutional biz (2% impact on revenue) and muted growth in acute ailment tests.In last 4 years, Metropolis has widened its lab network by 68% to 209 labs in 9MFY25. With sufficient lab network in place, the company’s focus ahead is on adding spokes and the target is to have 30 collection centres per lab as against 21 currently.Besides, new lab additions have dented its EBITDA margin by 100-150bps and the impact is likely to reverse ahead on the back of price hikes and operating leverage.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Metropolis Healthcare - Growth Levers Adequately in Place